Correction: Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma

Ihab Abd-Elrahman¹, Taher Nassar², Noha Khairi^{1

3}, Riki Perlman¹, Simon Benita², Dina Ben Yehuda^{4

5}

Affiliations

¹ Department of Hematology, Hadassah Medical Organization, Jerusalem, Israel.
² The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
³ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
⁴ Department of Hematology, Hadassah Medical Organization, Jerusalem, Israel. Dbyehuda@hadassah.org.il.
⁵ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Dbyehuda@hadassah.org.il.

Published Erratum

Ihab Abd-Elrahman et al. Oncogene. 2025 Mar.

. 2025 Mar;44(7):477.

doi: 10.1038/s41388-025-03282-7.

Ihab Abd-Elrahman¹, Taher Nassar², Noha Khairi^{1

3}, Riki Perlman¹, Simon Benita², Dina Ben Yehuda^{4

5}

¹ Department of Hematology, Hadassah Medical Organization, Jerusalem, Israel.
² The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
³ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
⁴ Department of Hematology, Hadassah Medical Organization, Jerusalem, Israel. Dbyehuda@hadassah.org.il.
⁵ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Dbyehuda@hadassah.org.il.

No abstract available

Erratum for

Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.
Abd-Elrahman I, Nassar T, Khairi N, Perlman R, Benita S, Ben Yehuda D. Abd-Elrahman I, et al. Oncogene. 2021 Jan;40(2):334-344. doi: 10.1038/s41388-020-01529-z. Epub 2020 Oct 30. Oncogene. 2021. PMID: 33128043